scholarly journals Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e107408 ◽  
Author(s):  
Daniel J. Sobczynski ◽  
Phapanin Charoenphol ◽  
Michael J. Heslinga ◽  
Peter J. Onyskiw ◽  
Katawut Namdee ◽  
...  
2016 ◽  
Vol 110 (3) ◽  
pp. 167a ◽  
Author(s):  
Marco De Spirito ◽  
Massimiliano Papi ◽  
Giuseppe Maolucci ◽  
Gabriele Ciasca ◽  
Valentina Palmieri ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2045
Author(s):  
Laís Ribovski ◽  
Naomi M. Hamelmann ◽  
Jos M. J. Paulusse

Safe and reliable entry to the brain is essential for successful diagnosis and treatment of diseases, but it still poses major challenges. As a result, many therapeutic approaches to treating disorders associated with the central nervous system (CNS) still only show limited success. Nano-sized systems are being explored as drug carriers and show great improvements in the delivery of many therapeutics. The systemic delivery of nanoparticles (NPs) or nanocarriers (NCs) to the brain involves reaching the neurovascular unit (NVU), being transported across the blood–brain barrier, (BBB) and accumulating in the brain. Each of these steps can benefit from specifically controlled properties of NPs. Here, we discuss how brain delivery by NPs can benefit from careful design of the NP properties. Properties such as size, charge, shape, and ligand functionalization are commonly addressed in the literature; however, properties such as ligand density, linker length, avidity, protein corona, and stiffness are insufficiently discussed. This is unfortunate since they present great value against multiple barriers encountered by the NPs before reaching the brain, particularly the BBB. We further highlight important examples utilizing targeting ligands and how functionalization parameters, e.g., ligand density and ligand properties, can affect the success of the nano-based delivery system.


1998 ◽  
Vol 13 (6) ◽  
pp. 439-446 ◽  
Author(s):  
Sean Allen

2018 ◽  
Vol 6 (18) ◽  
pp. 2803-2812 ◽  
Author(s):  
Marcelo de Sousa ◽  
Carlos H. Z. Martins ◽  
Lidiane S. Franqui ◽  
Leandro C. Fonseca ◽  
Fabrício S. Delite ◽  
...  

Graphene oxide mannosylation impacts on RBCs toxicity and plasma protein interactions.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Youyi Yu ◽  
Behafarid Ghalandari ◽  
Guangxia Shen ◽  
Liping Wang ◽  
Xiao Liu ◽  
...  

AbstractPhosphomolybdate-based nanoparticles (PMo12-based NPs) have been commonly applied in nanomedicine. However, upon contact with biofluids, proteins are quickly adsorbed onto the NPs surface to form a protein corona, which induces the opsonization and facilitates the rapid clearance of the NPs by macrophage uptake. Herein, we introduce a family of structurally homologous PMo12-based NPs (CDS-PMo12@PVPx(x = 0 ~ 1) NPs) capping diverse content of zwitterionic polymer poly (N-vinylpyrrolidone) (PVP) to regulate the protein corona formation on PMo12-based NPs. The fluorescence quenching data indicate that the introduction of PVP effectively reduces the number of binding sites of proteins on PMo12-based NPs. Molecular docking simulations results show that the contact surface area and binding energy of proteins to CDS-PMo12@PVP1 NPs are smaller than the CDS-PMo12@PVP0 NPs. The liquid chromatography-tandem mass spectrometry (LC–MS/MS) is further applied to analyze and quantify the compositions of the human plasma corona formation on CDS-PMo12@PVPx(x = 0 ~ 1) NPs. The number of plasma protein groups adsorption on CDS-PMo12@PVP1 NPs, compared to CDS-PMo12@PVP0 NPs, decreases from 372 to 271. In addition, 76 differentially adsorption proteins are identified between CDS-PMo12@PVP0 and CDS-PMo12@PVP1 NPs, in which apolipoprotein is up-regulated in CDS-PMo12@PVP1 NPs. The apolipoprotein adsorption onto the NPs is proposed to have dysoponic activity and enhance the circulation time of NPs. Our findings demonstrate that PVP grafting on PMo12-based NPs is a promising strategy to improve the anti-biofouling property for PMo12-based nanodrug design. Graphical Abstract


2019 ◽  
Vol 20 (11) ◽  
pp. 4208-4217 ◽  
Author(s):  
Ava Faridi ◽  
Wen Yang ◽  
Hannah Gabrielle Kelly ◽  
Chuanyu Wang ◽  
Pouya Faridi ◽  
...  

Author(s):  
J H Chesebro ◽  
V Fuster ◽  
J Byrne

The incidence of reinfarction, death and systemic thromboembolism is greatest in the first 2 months after acute myocardial infarction and decreases with time after infarction. Reasons for this are unknown, but increased platelet vascular wall interaction may be a contributing factor. Thirteen patients, mean age 53 years, had a platelet survival determination (platelet half-life calculated by least square analysis) within 1 month (mo) after acute, uncomplicated myocardial infarction (10 transmural, 3 subendocardial); a platelet survival study was repeated 3-8 mo (average 4 mo) later. All patients were on oral anticoagulants and during the time of observation none of the patients had any clinical thromboembolic events.Ten of the 13 patients had a shortened (<92 hours) platelet survival half-life of 75 hours (avg) within 1 mo after myocardial infarction which increased significantly (P<.01) to 94 hours (avg) four mo (avg) later. Ten control patients with angiographically proven coronary artery disease, stable angina pectoris, and a shortened platelet survival of 85 hours (avg) had a repeat platelet survival 6 mo later that was not significantly changed (mean variability 5%).The shortened platelet survival that improves with time after myocardial infarction is compatible with the increased incidence of reinfarction, death and thromboembolism early after myocardial infarction. Whether the increased platelet consumption reflects platelet deposition in the coronary vessels or in the left ventricle (as a mural thrombus) is at present under investigation with imaging of III-Indium-labeled platelets.


2020 ◽  
pp. 251-278
Author(s):  
Stefan Tenzer ◽  
Dominic Docter ◽  
Jörg Kuharev ◽  
Anna Musyanovych ◽  
Verena Fetz ◽  
...  

RSC Advances ◽  
2015 ◽  
Vol 5 (99) ◽  
pp. 81638-81641 ◽  
Author(s):  
M. Papi ◽  
M. C. Lauriola ◽  
V. Palmieri ◽  
G. Ciasca ◽  
G. Maulucci ◽  
...  

GO flakes, able to disrupt the erythrocyte plasma membrane, greatly reduce their haemolytic activity after interacting with plasma proteins. Haemolysis activity increases inversely to the GO flakes size.


Nanoscale ◽  
2017 ◽  
Vol 9 (36) ◽  
pp. 13651-13660 ◽  
Author(s):  
A. Solorio-Rodríguez ◽  
V. Escamilla-Rivera ◽  
M. Uribe-Ramírez ◽  
A. Chagolla ◽  
R. Winkler ◽  
...  

Differential profile in human and mouse plasma protein corona on SiO2NP in immune and coagulation processes indicate careful interpretation for safer nanomedicine design.


Sign in / Sign up

Export Citation Format

Share Document